UG and MUG's biotechnologists with the AMB grant

3.12.2021

The Laboratory of Recombinant Vaccines of the Intercollegiate Faculty of Biotechnology of the University of Gdańsk and the Medical University of Gdańsk is one of consortium members implementing project Development of novel mRNA/VLP-based vaccines against emerging zoonotic viral diseases, financed with almost 58,5 mln PLN by the Medical Research Agency (Agencja Badań Medycznych, ABM) under the programme Call for the development of innovative therapeutic solutions based on RNA technology. IFB UG&MUG’s research team headed by Prof. Bogusław Szewczyk from the UG obtained 11,5 mln PLN from that.

scientists from the IFB UG&MUG, first from the left is Prof. Bogusław Szewczyk, photo by UG

The project’s objective is to come to the clinical research stage recombinant potential antiviral vaccines based on mRNA and virus-like particles (VLP). Vaccines against viral zoonoses, primarily the ones caused by SARS-CoV-2, tick-borne encephalitis virus and West Nile virus.

Remaining consortium members are the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences and Adamed Pharma company. Total project’s budget amounts to 88 mln PLN. Full rank list is available at the ABM website.